Merck Osteoporosis Drug Builds Bone Density in Mid-Stage Trial
Merck osteoporosis drug builds bone density in mid-stage trial
Filed under: drug treatment news 2012
(Reuters) – Hip and spine bone mineral density increased significantly among post-menopausal women on Merck & Co's experimental new osteoporosis drug who had previously taken a standard older company treatment, the drugmaker said on Saturday.
Read more on Reuters
ADHD study reveals children's views
Filed under: drug treatment news 2012
Critics say medication is the wrong way to go and that ADHD (attention deficit hyperactivity disorder) is an extreme form of normal behaviour that needs understanding and psychological therapy rather than drugs. But, said biomedical ethicist Dr Ilina …
Read more on The Guardian
EMCDDA – EUROPEAN MONITORING CENTRE FOR DRUGS AND : 15.10 …
Filed under: drug treatment news 2012
'The significant number of problem drug users who have accessed European drug treatment services in recent years reflects an important step towards integration', says the report. But, it adds, 'neglecting the social needs of clients can undermine the …
Read more on 4-traders
New analysis indicates that Novartis drug Gilenya shows significant early …
Filed under: drug treatment news 2012
Basel, October 12, 2012 – New data will be presented at the 28th congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) that reinforce the generally early and sustained efficacy benefit and long-term safety …
Read more on Reuters
Merck Osteoporosis Drug Builds Bone Density In Mid-stage Trial
(Reuters) – Hip and spine bone mineral density increased significantly among post-menopausal women on Merck & Co's experimental new osteoporosis drug who had previously taken a standard older company treatment, the drugmaker said on Saturday. The favorable results were seen in a mid-stage trial of Merck's odanacatib, a once-weekly pill which works by blocking an enzyme called cat-K found within … Read News